Similarly, AML cells, particularly those harboring FLT3 mutations, modulate their metabolic pathways dynamically in response to nutrient availability, microenvironmental stress, and therapeutic pressure (Figure 1) [41,42]. This evidence concerns the gene FLT3 and acute myeloid leukemia.